References
- Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil. Neural Repair17, 66–70 (2003).
- Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehab.24, 293–304 (2010).
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler.10, 589–595 (2004).
- Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev. Neurother.12(Suppl. 4), 3–8 (2012).
- Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev. Pharmacoecon. Outcomes Res.11, 205–213 (2011).
- Flachenecker P, Henze T, Hengsbach M, Ehlken B, Zettl UK. Spasticity in multiple sclerosis – a cross-sectional survey in Germany. Mult. Scler.18, S21 (2012).
- Kobelt G, Lindgren P, Smala A; the German MS Study Group. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur. J. Health Econ.2, 60–68 (2001).
- Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia5, 378–385 (1999).
- Groen H, van der Bij W, Koëter GH, TenVergert EM. Cost–effectiveness of lung transplantation in relation to type of end-stage pulmonary disease. Am. J. Transplantation4, 1155–1162 (2004).